CRS 3123
Alternative Names: CRS3123; REP 3123Latest Information Update: 14 Jun 2021
At a glance
- Originator Replidyne
- Developer Crestone; National Institute of Allergy and Infectious Diseases
- Class Amines; Antibacterials; Chromans; Halogenated hydrocarbons; Pyridines; Pyridones; Small molecules
- Mechanism of Action Methionine tRNA ligase inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Clostridium difficile infections
Most Recent Events
- 14 Jun 2021 CRS 3123 is still in phase I trial in Clostridium-difficile-infections(In volunteers) in USA (PO, Capsule) (NCT04781387)
- 07 Jun 2021 CRS 3123 receives Fast Track designation for Clostridium difficile infections [PO,Capsule] (In the elderly, In adults) in USA
- 07 Jun 2021 CRS 3123 receives Qualified Infectious Disease Product status for Clostridium difficile infections in USA